Table 3 Subgroup analysis of association between exposure to HPV Vaccination and spontaneous abortion
Number of studies included | Vaccine exposure group (total, n) | Vaccine exposure group (SA, n) | Control group (total, n) | Control group (SA, n) | RR | 95% CI | I 2 | RD (%) | 95% CI (%) | I 2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
2vHPV (Pre-90 days to pregnancy end) | |||||||||||
Data source | |||||||||||
Clinical Trials base | 2 | 846 | 121 | 3676 | 464 | 1.16 | 0.88–1.55 | 42.7 | 2.0 | −1.7-5.7 | 43.5 |
Database | 1 | 330 | 34 | 632 | 57 | 1.14 | 0.76–1.71 | – | 1.3 | −2.7-5.3 | – |
Adjusted data or not | |||||||||||
Adjusted a | 2 | 711 | 84 | 3859 | 471 | 1.03 | 0.90–1.19 | 0.0 | – | – | – |
Unadjusted | 1 | 465 | 71 | 449 | 50 | 1.37 | 0.98–1.39 | – | – | – | – |
4vHPV (Pre-45 days to pregnancy end) | |||||||||||
Data source | |||||||||||
Clinical trials base | 2 | 213 | 31 | 1486 | 180 | 0.85 | 0.57–1.27 | 0.0 | −2.2 | −7.8-3.4 | 0.0 |
Database | 2 | 2344 | 207 | 2771 | 209 | 0.89 | 0.72–1.09 | 20.2 | −1.0 | −2.7-0.7 | 0.0 |
Adjusted data or not | |||||||||||
Adjusted a | 2 | 2344 | 207 | 2771 | 209 | 1.06 | 0.85–1.32 | 13.7 | – | – | – |
Unadjusted | 2 | 213 | 31 | 1486 | 180 | 0.85 | 0.57–1.27 | 0.0 | – | – | – |